The Biological Effects of Interleukin-6 and Their Clinical Applications in Autoimmune Diseases and Cancers

<p>Interleukin-6 (IL-6) is one of the pro-infl ammatory cytokines involved in pathogenesis of various  autoimmune and chronic infl ammatory diseases. IL-6 through binding to its cellular receptor can transduce both classical- and trans-signaling pathways. Overproduction of circulating IL-6 can...

সম্পূর্ণ বিবরণ

সংরক্ষণ করুন:
গ্রন্থ-পঞ্জীর বিবরন
প্রধান লেখক: Deng-Ho Yang (লেখক)
বিন্যাস: গ্রন্থ
প্রকাশিত: Rheumatica Acta: Open Access - Peertechz Publications, 2017-03-02.
বিষয়গুলি:
অনলাইন ব্যবহার করুন:Connect to this object online.
ট্যাগগুলো: ট্যাগ যুক্ত করুন
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!

MARC

LEADER 00000 am a22000003u 4500
001 peertech__10_17352_raoa_000003
042 |a dc 
100 1 0 |a Deng-Ho Yang  |e author 
245 0 0 |a The Biological Effects of Interleukin-6 and Their Clinical Applications in Autoimmune Diseases and Cancers 
260 |b Rheumatica Acta: Open Access - Peertechz Publications,   |c 2017-03-02. 
520 |a <p>Interleukin-6 (IL-6) is one of the pro-infl ammatory cytokines involved in pathogenesis of various  autoimmune and chronic infl ammatory diseases. IL-6 through binding to its cellular receptor can transduce both classical- and trans-signaling pathways. Overproduction of circulating IL-6 can be  detected in patients with different autoimmune diseases. Tocilizumab, a humanized monoclonal antibody against IL-6 receptor, can block IL-6-mediated signaling and has been approved for the treatment of rheumatoid arthritis and Castleman's disease. Besides, expression of IL-6 may promote tumorigenesis and has been detected in various tumors, including multiple myeloma, colorectal cancer, breast cancer, lymphoma, breast cancer and lung cancer. Furthermore, increased levels of circulating IL-6 are  associated with poor prognosis and cachexia in cancer patients. Monotherapy with IL-6 blockade or a combination therapy with both IL-6 blockade and conventional chemotherapy may reduce the progression of cancer and improve the status of cachexia in cancer patients. Finally, based upon the known biological effects of IL-6, diseases, other than autoimmune diseases and cancers, potentially to be anti-IL-6 candidates will be briefl y discussed.</p> 
540 |a Copyright © Deng-Ho Yang et al. 
546 |a en 
655 7 |a Review Article  |2 local 
856 4 1 |u https://doi.org/10.17352/raoa.000003  |z Connect to this object online.